Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, has announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution. OPUS-2 compared lifitegrast to placebo administered twice daily for 84 days (12 weeks) in dry eye patients with history of active artificial tear use within 30 days prior to screening.
More...
iHav.net - Your Uncensored Offtopic Community
If this is your first visit, please click the Sign Up now button to begin the process of creating your account so you can begin posting on our forums! The Sign Up process will only take up about a minute of two of your time.
|
|
|
Results 1 to 1 of 1
-
12-10-2013, 02:00 PM #1Senior Member
- Join Date
- Mar 2008
- Posts
- 12,518
- Downloads
- 0
- Uploads
- 0
Shire reports top-line results on OPUS-2, a Phase 3 study investigating the use of Li
Reply With QuoteSimilar Threads
-
BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 12-09-2010, 02:00 PM -
Merck Reports Initial Results Of Phase III Study Of ISENTRESS® (raltegravir)
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 12-01-2010, 02:31 PM -
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investiga
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 10-25-2010, 01:00 PM -
Alnylam Publishes Results From Phase IIa Study Of ALN-RSV01 In The Treatment Of Respi
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 10-05-2010, 01:00 PM -
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 01-30-2010, 01:03 PM
Bookmarks